Answers are grounded in this paper and cite their sources.
This editorial refers to ‘Interleukin 6 trans-signalling and risk of future cardiovascular events’ by L. Ziegler et al., pp. 213–221. More than 20 years ago, pivotal studies reported that an increased C-reactive protein (CRP) level predicted poor outcome in patients with acute coronary syndrome, raising the hypothesis that systemic inflammation could be involved in the pathogenesis of the disease.1,2 Since then, high sensitivity (hs)CRP has emerged as a powerful risk biomarker for cardiovascular events (CVE) in healthy individuals. Indeed, increased hsCRP (per 1-standard deviation higher log(e) CRP concentration) was associated with a multivariable-adjusted relative risk (RR) of 1.37 [95% confidence interval (CI) 1.27–1.48] for new onset coronary heart disease and of 1.55 (95% CI 1.37–1.76) for cardiovascular mortality in a meta-analysis of prospective studies including >160 000 individuals without a history of vascular disease.3 Nevertheless, a causal role for CRP in coronary atherothrombosis could not be demonstrated, owing to reverse causality in case–control studies, nor was it confirmed in genetic Mendelian randomization studies. Indeed, CRP is a primary acute-phase reactant, which is mainly produced in the liver in response to multiple inflammatory stimuli and circulating cytokines, in particular interleukin (IL)-6, although it can also be produced by local inflammatory cells.4 Much evidence now exists that inflammatory mechanisms are key regulators of atherosclerosis and coronary plaque instability.5 CRP is the final downstream biomarker of a complex inflammatory pathway which includes upstream IL-1 and intermediate IL-6 signalling pathways.6 In the classical signalling pathway, IL-6 binds directly to the cellular membrane-bound IL-6 receptor (IL-6R) (expressed on hepatocytes and several white blood cells) and forms a signalling complex with the membrane-bound glycoprotein 130 (gp130).7 This pathway mainly mediates the regenerative and antibacterial effects of IL-6. In contrast, in the trans-signalling pathway, the circulating binary complex composed of IL-6 and the circulating soluble portion of IL-6R, i.e. IL-6/sIL-6R, activates membrane-bound gp130 in those cells that do not express membrane-bound IL-6R.7 Fine-tune regulation of the binary complex activity occurs by the circulating soluble portion of gp130 (sgp130), which binds the binary IL-6/sIL-6R complex, forming the IL-6:sIL-6R:sgp130 ternary complex, and blocks the activation of membrane-bound gp130. The trans-signalling pathway has been shown to have pro-inflammatory activities.7 At variance with CRP, several studies have supported a causal role for the IL-6 signalling pathway in coronary atherosclerosis and its complications. Indeed, IL-6 was associated with a multivariable-adjusted RR of 1.25 (95% CI 1.19–1.32), per 1-standard deviation higher log-transformed baseline levels, for non-fatal myocardial infarction or coronary death in a meta-analysis of up to 29 population-based prospective studies.8 Mendelian randomization studies have reported association in the IL6-R gene between a single nucleotide polymorphism (rs7529229) marking a non-synonymous IL6-R variant (rs2228145; p.Asp358Ala) and coronary heart disease events.9,10 Indeed, the variant Asp358Ala in IL-6R was associated with reduced risk of coronary heart disease in a dose-dependent manner.10 This variant results in a higher circulating level of soluble IL-6R, with a paradoxical increase in IL-6 level and lower levels of hsCRP and fibrinogen, indicating reduced transduction of the IL-6 signalling pathway. Nevertheless, from this study, one cannot disentangle the relative inhibitory effect of the genetic variant on the classical or trans-signalling IL-6 pathway. Previous studies have shown that higher levels of sIL-6R could potentiate the antagonistic activity of sgp130 on IL-6 response,11 probably owing to a higher concentration of sgp130 than sIL-6R, leading to reduced IL-6 trans-signalling.12 Ziegler et al.13 investigate whether IL-6 trans-signalling, assessed by the ratio of the IL-6/sIL-6R binary complex to the IL-6:sIL-6R:sgp130 ternary complex, is associated with the risk of first time composite of CVE, defined as coronary heart disease, myocardial infarction, sudden cardiac death and ischaemic stroke, in a Swedish cohort of 4232 60-year-old men and women. The authors report that each 0.1 unit increase in the binary/ternary complex ratio is associated with a multivariable-adjusted RR of 1.31 for future CVE (95% CI 1.13–1.51). Nevertheless, the binary/ternary complex ratio did not predict cardiovascular mortality. Further, its incremental value, as assessed by the area under the curve (AUC) or the net reclassification index (NRI), in comparison to the Framingham risk score (FRS), with and without IL-6 in the regression model, was only modest. Indeed, AUC was 0.62 (0.59–0.64) for a model containing FRS plus IL-6 plus binary/ternary complex ratio vs. 0.59 (0.56–0.62) for a model containing FRS plus IL6, and NRI increased by 0.1 only. One limitation of the study is the lack of assessment of the predictive value of the binary/ternary complex ratio on clinical outcomes after adjustment for baseline hsCRP. Therefore, while the study’s findings cannot provide a definite answer on the clinical usefulness of the binary/ternary complex ratio as an alternative, stand-alone biomarker for cardiovascular risk prediction in healthy individuals, the study does support the notion that IL-6 trans-signalling activity plays a pivotal role in the pathogenesis of CVE. Most importantly, the study opens the avenue to future research testing the hypothesis that pharmacological strategies aiming at lowering the binary/ternary complex ratio by increasing the ternary complex, and thus enhancing the antagonistic activity of the system on IL-6 response, could reduce the risk of CVE. In this regard, a population-based case control study involving 664 cases and 1, 062 controls showed that very high levels of the anti-inflammatory sgp130 were associated with a 30% RR reduction of myocardial infarction (odds ratio 0.7, 95% CI 0.5–0.9).14 Further, treatment with an sgp130–IgG1-Fc fusion protein (sgp130Fc) led to a dramatic reduction in atherosclerosis in hypercholesterolaemic LDLr−/− mice without affecting weight gain or serum lipid levels as well as to significant regression of advanced atherosclerosis.15 These effects were paralleled by reductions in endothelial activation, intimal smooth muscle cell infiltration, monocyte recruitment, and subsequent atherosclerotic plaque progression.15 Therefore, treatment options, such as sgp130Fc, that specifically block IL-6 trans-signalling without affecting classic signalling, and thus that minimize the risk of blunting physiological inflammatory responses, deserve future investigations in ad hoc-designed randomized clinical trials for the treatment and prevention of cardiovascular disease. Conflict ofinterest: none declared. This work was supported by the European Research Council, Advanced Grant [294609, CardioEpigen] and Proof of Concept Grant [713734]; the Italian Ministry of Health [PE-2013-02356818]; the Cariplo Foundation [2015-0573]; and the Italian Ministry of Education, University and Research [2015583WMX], all to G.C.
No takes yet. Share an insight, caveat, or question.
Ferrante et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: